Show simple item record

dc.contributor.authorBoughton, Charlotte K.
dc.contributor.authorDaly, Aideen
dc.contributor.authorThabit, Hood
dc.contributor.authorHartnell, Sara
dc.contributor.authorHerzig, David
dc.contributor.authorVogt, Andreas
dc.contributor.authorRuan, Yue
dc.contributor.authorWilinska, Malgorzata E.
dc.contributor.authorEvans, Mark L.
dc.contributor.authorColl, Anthony P.
dc.contributor.authorBally, Lia
dc.contributor.authorHovorka, Roman
dc.date.accessioned2021-05-04T08:09:37Z
dc.date.available2021-05-04T08:09:37Z
dc.date.issued2021-05-04
dc.date.submitted2021-03-03
dc.identifier.citationDiabetes, Obesity and Metabolism
dc.identifier.issn1462-8902
dc.identifier.issn1463-1326
dc.identifier.otherdom14396
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/321893
dc.descriptionFunder: and the Swiss Diabetes Foundation
dc.description.abstractAbstract: The aim of this study was to characterize the variability of exogenous insulin requirements during fully closed‐loop insulin delivery in hospitalized patients with type 2 diabetes or new‐onset hyperglycaemia, and to determine patient‐related characteristics associated with higher variability of insulin requirements. We retrospectively analysed data from two fully closed‐loop inpatient studies involving adults with type 2 diabetes or new‐onset hyperglycaemia requiring insulin therapy. The coefficient of variation quantified day‐to‐day variability of exogenous insulin requirements during up to 15 days using fully automated closed‐loop insulin delivery. Data from 535 days in 67 participants were analysed. The coefficient of variation of day‐to‐day exogenous insulin requirements was 30% ± 16%, and was higher between nights than between any daytime period (56% ± 29% overnight [11:00 pm to 4:59 am] compared with 41% ± 21% in the morning [5:00 am to 10:59 am], 39% ± 15% in the afternoon [11:00 am to 4:59 pm] and 45% ± 19% during the evening [5:00 pm to 10:59 pm]; all P < 0.01). There is high day‐to‐day variability of exogenous insulin requirements in inpatients, particularly overnight, and diabetes management approaches should account for this variability.
dc.languageen
dc.publisherBlackwell Publishing Ltd
dc.subjectBRIEF REPORT
dc.subjectBRIEF REPORTS
dc.subjectcontinuous glucose monitoring (CGM)
dc.subjectdiabetes complications
dc.subjectinsulin pump therapy
dc.subjectinsulin therapy
dc.subjectobservational study
dc.subjecttype 2 diabetes
dc.titleDay‐to‐day variability of insulin requirements in the inpatient setting: Observations during fully closed‐loop insulin delivery
dc.typeOther
dc.date.updated2021-05-04T08:09:36Z
dc.identifier.doi10.17863/CAM.69352
dcterms.dateAccepted2021-03-31
rioxxterms.versionofrecord10.1111/dom.14396
rioxxterms.versionAO
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidBoughton, Charlotte K. [0000-0003-3272-9544]
dc.contributor.orcidDaly, Aideen [0000-0001-5003-9630]
dc.contributor.orcidHerzig, David [0000-0003-1028-9445]
dc.contributor.orcidRuan, Yue [0000-0003-3498-2543]
dc.contributor.orcidEvans, Mark L. [0000-0001-8122-8987]
dc.contributor.orcidBally, Lia [0000-0003-1993-7672]
pubs.funder-project-idClinical studies received support from Diabetes UK (#14/0004878)
pubs.funder-project-idSwiss National Science Foundation (P1BEP3_165297)
pubs.funder-project-idand European Foundation for the Study of Diabetes. Additional support for the Artificial Pancreas work by JDRF, National Institute for Health Research Cambridge Biomedical Research Centre and Wellcome Trust Strategic Award (100574/Z/12/Z)
pubs.funder-project-idAbbott Diabetes Care supplied discounted continuous glucose monitoring devices, sensors, and details of communication protocol to facilitate real‐time connectivity. LB received financial support from the University Hospital Bern, University of Bern, Swiss National Science Foundation (P1BEP3_165297)


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record